Should the ASCO/ASH guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 5, 2014, Pages 657-664

  Gafter Gvili, Anat ^a,b   Steensma, David P ^c   Auerbach, Michael ^d  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; DIPHENHYDRAMINE; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; HEPCIDIN; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ANAPHYLACTOID PURPURA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PROTOCOL; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GOLD STANDARD; HEMOGLOBIN BLOOD LEVEL; HISTOCHEMISTRY; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MULTICENTER STUDY (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ANEMIA; CHEMICALLY INDUCED; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS; PRACTICE GUIDELINE;

ADMINISTRATION, INTRAVENOUS; ANEMIA; ANTINEOPLASTIC AGENTS; HUMANS; IRON; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84900386818     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0069     Document Type: Review

References (35)

1. Auerbach M, Ballard H, Trout J, et al. Intravenous iron optimizes the response to recombinant erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307. (Pubitemid 41079845)
2. Henry DH, Dahl NV, Auerbach MA, et al. Intravenous ferric gluconate significantly improves response to epoetin alpha versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
3. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin doses requirement in anemic patients with lymphoproliferative malignancies: a randomized, multicenter study. Leukemia 2007;21:627-632. Erratum in Leukemia 2008;22:462. (Pubitemid 46444544)
4. Bastit L, Vandbroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with and without intravenous iron in patients with chemotherapy induced anemia. J Clin Oncol 2008;26:1611-1618.
5. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
6. Auerbach M, Silberstein P, Webb R, et al. Darbepoetin alfa 300 or 500 μg once every three weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85:655-663.
7. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol 2013;88:990-996.
8. Steinmetz H, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anemia. Ann Oncol 2013;24:475-482.
9. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199-204. (Pubitemid 46441460)
10. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116:522-525.
11. Anthony LB, Gabrail NY, Ghazal H, et al. IV iron sucrose for cancer- and/or chemotherapy-induced anemia in patients treated with erythropoiesis- stimulating agents. Commun Oncol 2011;8:270-278.
12. Steensma D, Sloan J, Dakhil S, et al. Phases III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97-105.
13. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.
14. Rodgers GM, Gilreath JA, Cella D, et al. NCCN Clinical Practice Guidelines in Oncology: Cancer-and Chemotherapy-Induced Anemia. Version 3.2014. Available at: http://www.nccn.org/professionals/physician-gls/PDF/anemia.pdf. Accessed March 30, 2014.
15. Schrijvers D, De Samblanx H, Roila F, for the ESMO Guidelines Working Groups. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann Oncol 2010;21(Suppl 5):v244-247.
16. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trial. Lancet 2009;373:1532-1542.
17. Vansteenkiste J, Glaspy J, Henry D, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analysis. Lung Cancer 2012;76:475-485.
18. Moebus V, Jackisch C, Schneeweiss A, et al. Adding epoetin alpha to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013;105:1018-1026.
19. Nitz U, Gluz O, Zuna I, et al. Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann Oncol 2014;25:75-80.
20. Rodgers G, Auerbach M, Cella D, et al. High-molecular-weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008;19:833-834.
21. Chandler G, Harchowal J, MacDougall I. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001;38:988-991. (Pubitemid 33022176)
22. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin alfa and IV iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter [abstract]. Blood 2008;112(Suppl):Abstract 54.
23. Steensma D, Sasu B, Tomita D, et al. The relationship between serum hepcidin levels and clinical outcome in patients with chemotherapy-associated anemia treated in a controlled trial [abstract]. J Clin Oncol 2011;29(Suppl 1):Abstract 9031.
24. Loo M, Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 1999;93:3286-3293. (Pubitemid 29220895)
25. Henry D, Dahl N, Auerbach M. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012;87:308-310.
26. Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012;138:179-187.
27. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anemia - systematic review and meta-analysis of randomised trials. Acta Oncol 2013;52:18-29.
28. Auerbach M, Liang A, Glaspy J. Intravenous iron in chemotherapy and cancer-related anemia. Commun Oncol 2012;9:289-295.
29. DexFerrum [package insert]. Shirley, NY: American Regent, Inc; 2008.
30. INFeD [package insert]. Morristown, NJ: Watson Pharma, Inc; 2009.
31. Ferrlecit [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2011.
32. Venofer [package insert]. Shirley, NY: American Regent, Inc; 2000.
33. Feraheme [package insert]. Waltham, MA: AMAG Pharmaceuticals, Inc; 2014.
34. Injectafer [package insert]. Shirley, NY: American Regent, Inc; 2013.
35. MonoFer [package insert]. Holbaek, Denmark: Pharmacosmos A/S; 2012.